Healthcare enterprise platform Azra AI and 4DMedical Limited (ASX: 4DX), a provider of quantitative lung imaging analytics, on Monday announced a strategic OEM and reseller partnership to provide health systems with enterprise-wide lung health intelligence.

4DMedical will resell Azra AI's real-time patient-identification platform, enabling customers to identify and coordinate care for patients with pulmonary nodules and other lung-related conditions.

Under the partnership, Azra AI's artificial intelligence analysis of radiology reports will be combined with 4DMedical's quantitative lung imaging analytics, providing clinicians with imaging-based detection and measurable clinical data to support care decisions.

The offering will cover COPD and emphysema, interstitial lung disease, pulmonary nodules, unexplained breathlessness, coronary artery calcification, and acute and chronic pulmonary embolism. Patients identified through radiology reports and imaging can be automatically routed to appropriate care teams, with Azra AI tracking their progress through scheduling, imaging and follow-up.